NCT06000033View on ClinicalTrials.gov

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

Disitamab Vedotin+Anlotinib

Disitamab Vedotin:2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER